Your first document may be a colonoscopy report, an MRI scan or a letter from your gastroenterologist. Before you compare treatment abroad, that document needs to show what Crohn’s disease is doing in your body. A painful perianal fistula and widespread inflammation inside the bowel call for very different discussions about stem cells.
As you collect reports, plans and discharge papers, use them to test each overseas proposal. Stem cell therapy is not a routine cure for Crohn’s disease. Its evidence, risks and regulatory status depend heavily on the cell treatment being proposed and the problem it is meant to address.
Your Crohn’s reports: Where is the disease, and how severe is it?
Ask your home specialist for recent endoscopy, biopsy and imaging reports before requesting an overseas assessment. Luminal Crohn’s disease means inflammation within the digestive tract. Reports may locate it in the ileum, the last part of the small bowel, in the colon, or in both. They should also describe whether inflammation is active, whether ulcers are present and whether previous surgery has been followed by recurrence.
For a fistula near the anus, pelvic MRI and an examination by a colorectal surgeon help map its branches and any collection of infection. A complex perianal fistula is an abnormal tunnel that may branch, cross important muscles, recur or occur alongside an abscess. Reports may use terms such as “fistulizing” or “penetrating” for disease that creates tunnels through tissue. A stricture is a narrowed bowel segment. If scar tissue is causing blockage, cell therapy will not simply remove that narrowing.
Clinicians assess severity using symptoms, blood and stool inflammation tests, endoscopy and imaging rather than a single grade. A report may contain a SES-CD score for bowel inflammation, a Rutgeerts score for inflammation after bowel surgery, or an MRI description of fistula activity. Overseas teams may use different scoring systems or translated wording. Ask them to state the actual findings, not just label your Crohn’s “severe.”
Stem cells are studied most directly for selected complex perianal fistulas and, through a very different procedure, for highly treatment-resistant luminal disease. Ileal, colonic, ileocolonic, stricturing, penetrating and postoperative Crohn’s are not interchangeable indications. Children and adolescents need pediatric specialist assessment, generally within a research setting. Keep the original reports and images, not only a short summary, for both the overseas team and your doctor at home.
Your referral: Why consider stem cells instead of another Crohn’s treatment?
A useful referral explains which treatments you have tried, why they were stopped, what has failed to heal and what remains possible. Include medicine names, responses and side effects, previous fistula procedures or bowel operations, and any history of serious infection. A clinic can use these records for a preliminary remote assessment. It cannot give final medical clearance until its specialists review you in person and complete any necessary tests.
The referral should also show that conventional options have been considered. These may include adjusting medicines with your gastroenterologist, nutritional support, drainage of an abscess, a seton to keep a fistula draining, further fistula surgery or bowel surgery where appropriate. Having the same procedure near home may make appointments and complication care easier. Treatment abroad may offer access to a particular specialist team or research study, but travel can make continuity harder.
For a complex perianal fistula
Ask whether infection has been drained, active bowel inflammation is controlled and a colorectal surgeon considers local cell treatment suitable. An untreated abscess needs attention before a cell injection is considered.
For refractory luminal disease
Ask for a multidisciplinary review of remaining medical and surgical options. A stem cell transplant is a high-risk intervention for a small, carefully selected group, not a substitute for routine Crohn’s care.
Age alone does not decide eligibility, but frailty, heart or lung disease, diabetes, smoking and a high body mass index can affect anesthesia, infection risk and healing. Previous cancers or infections may be especially relevant to transplant assessment. Your referral should make these issues visible rather than leaving them for a surprise decision after you travel.
Your overseas treatment plan: Which cells, which procedure, and which evidence?
“Stem cell therapy” can describe two substantially different approaches. Require the written plan to name the cell type, its source, how it is processed, how it is given and whether its use for your condition is authorized, restricted to a trial or otherwise regulated in the destination. Product names and the words used for regulatory status can differ across borders. A familiar brand name does not establish that the proposed use is appropriate or available where you plan to receive care.
Compare the proposed approach with the problem shown in your reports:
| Approach | Main setting studied | What to verify in writing |
|---|---|---|
| Mesenchymal stromal cells (MSCs) | Selected complex perianal fistulas after surgical preparation | Cell source, product or manufacturer, regulatory status, surgical steps and follow-up imaging |
| Hematopoietic stem cell transplantation (HSCT) | Highly selected, severe treatment-resistant disease in specialist or research care | Transplant protocol, chemotherapy, infection support, fertility counseling and long-term monitoring |
| Unspecified “stem cell infusion” | No clear Crohn’s indication established by the phrase alone | Exact cells, rationale, evidence, authorization and why this route should treat your documented disease |
For fistulas, MSCs are typically placed locally after the tract has been prepared. For HSCT, your own blood-forming stem cells are generally collected, strong chemotherapy suppresses your immune system, and the collected cells are returned so blood-cell production can recover. The risks and recovery are therefore not comparable. An offer that calls either procedure simply an “injection” leaves out information you need to consent.
Compare plans on the diagnosis they accept, the named treating gastroenterologist, surgeon or transplant team, the product and its source, facility capabilities, complication arrangements and follow-up. For local MSC treatment, ask who performs the fistula surgery and how abscesses are managed. For HSCT, ask about transplant-unit licensing, infection-control support and the team’s experience with autoimmune disease. Relevant hospital accreditation may help you assess systems, but it does not replace proof that this specific service is licensed and appropriately staffed.
The financial proposal should be just as specific. Comparable international price ranges are not dependable without knowing which of these procedures is proposed, and a procedure quote is not your total cost of traveling for care. Ask for written inclusions and exclusions covering consultations, diagnostics, cell collection or product, processing, surgery or transplant care, anesthesia, hospital care, medicines, management of complications, accommodation, transfers and follow-up. The lowest quote is not automatically the best clinical fit.
Availability, approval rules, trial access and specialist services vary between destinations. A PlacidWay patient coordinator can help you compare relevant destinations, prices and travel arrangements without replacing a specialist’s clinical advice.
Your pre-procedure sheet: What must be done before departure?
Most preparation begins at home. Send the overseas team your recent endoscopy and biopsy findings, MRI or other imaging files, blood and stool test results, medication list, allergies, vaccination history and reports from previous operations. Include your full medical history and your home gastroenterologist’s contact details. Ask which results need repeating after you arrive and which finding could make the team postpone treatment.
Your instruction sheet should turn the proposed procedure into practical checks:
- ✓ Infection review: Report fever, a new abscess or other infection promptly. A transplant assessment also calls for extensive infection screening.
- ✓ Medicine reconciliation: Have your specialists agree on any changes to biologics, steroids, blood thinners or other medicines. Do not stop them on the basis of a travel itinerary.
- ✓ Health and nutrition: Discuss anemia, poor intake, diabetes control, smoking and other factors that could complicate healing or recovery.
- ✓ Home-care contact: Confirm that a local gastroenterologist knows the proposed treatment and can receive records when you return.
- ✓ Arrival assessment: Ask which in-person examination, imaging, anesthesia review or laboratory results are required for final clearance.
Plan to remain accessible to the treating team for the assessments and early monitoring your procedure requires. Fistula surgery and transplantation create very different demands on mobility, supervision and help from a companion. Ask your team when travel home is medically reasonable in your individual case rather than relying on a package itinerary.
Your consent form: Which risks are you accepting far from home?
Consent should identify the exact procedure and its realistic goal. For a fistula, that may be combined remission, meaning the external openings have stopped draining and imaging does not show a substantial active collection. In selected MSC studies, roughly four to six in ten treated patients have met remission measures around medium-term follow-up. Definitions, background treatment and results vary by patient and study. Closure may not last, and an apparently closed opening does not prove that Crohn’s elsewhere is controlled.
For local fistula treatment, the consent discussion should cover pain, bleeding, anesthesia complications, persistent drainage, recurrent fistula and abscess. Published abscess rates vary with the study, its follow-up and the surgical care given alongside cells. Ask the team for its own audited rates and for the rates observed in the evidence supporting the product it proposes. An abscess can require urgent drainage and antibiotics, not just a video consultation.
HSCT carries substantially greater risk. Chemotherapy causes a period of very low blood counts, when serious infection, bleeding and organ complications can occur. Infertility and treatment-related death are possible, and Crohn’s can relapse after an initial response. Because transplant protocols and patient selection differ, a general success or complication percentage cannot reliably predict your result. Ask for the treating unit’s outcomes, the possibility of intensive care and how it provides urgent support after discharge.
Cross-border safety question: Before paying a deposit, ask who answers urgent calls after you return home, which problems require immediate local assessment, and who pays for and arranges further treatment if the fistula recurs or transplant complications arise. A guarantee of cure is not an adequate complication plan.
A credible consent process gives you time to ask about alternatives, expected benefit, uncertainty and the option not to proceed. Your plan should identify the actual treating provider, proposed technique, major costs and exclusions, recovery expectations and responsibilities after you leave. Seek clarification if success claims have no defined outcome or follow-up period.
Your procedure record: What was actually done?
After treatment, request an operative note or transplant record rather than relying on the original proposal. The sequence below helps you check whether it matches what you consented to:
- Fistula mapping and preparation. For local MSC treatment, the surgeon examines the fistula, addresses infection, cleans the tract and closes its internal opening where appropriate.
- Cell administration. The note should state the product or cell source, batch information where applicable, treatment site and any departure from the planned technique.
- Collection and conditioning for HSCT. If you undergo transplant instead, the record should document stem cell collection and the chemotherapy used to prepare your body.
- Infusion and monitoring for HSCT. It should record the returned cells, immediate reactions and the plan for blood-count recovery and infection monitoring.
These are alternative pathways, not steps that every patient receives. For a fistula procedure, keep the operative note and any cell-product identification with your MRI reports. For HSCT, keep the transplant summary, cell-source details and complication record. Your local team needs to know what entered your body and what other treatment accompanied it.
Your discharge summary: What should recovery look like at home?
The first recovery milestones happen near the treating team. After local fistula treatment, clinicians check pain, bleeding, drainage and signs of infection before handing monitoring over to you and your home doctor. Fistula healing is assessed over later follow-up, often with examination and sometimes MRI. Persistent symptoms need review even if the outside opening looks better.
After HSCT, early recovery is more intensive. The transplant unit monitors low blood counts, infection risk, organ function and the return of blood-cell production. Follow-up continues after you return home because immune recovery and Crohn’s activity require ongoing assessment. Discharge from the hospital is not the same as completion of transplant care.
Read the discharge summary for your diagnosis, procedure, medicines, test results, complications and pending results. Terms can vary across health systems: engraftment means transplanted cells have begun producing blood cells, while clinical remission describes improvement under a specified clinical measure, not a permanent cure. Ask the team to translate unfamiliar terms and provide the report in a form your local doctor can use.
Seek urgent local care for fever, worsening rectal pain or swelling, heavy bleeding, severe abdominal pain, dehydration or symptoms of bowel blockage. After HSCT, fever or a sudden deterioration needs particularly prompt medical attention. Contact the overseas team as your written plan directs, but do not wait for a remote reply when you may need an examination, imaging, drainage or hospital care.
Your follow-up plan: Who checks remission, relapse and future treatment?
Before leaving, obtain a written schedule for symptoms, blood and stool tests, imaging and specialist review. It should say which appointments the overseas team will provide remotely and which your home gastroenterologist or colorectal surgeon must arrange. Keep emergency contacts, prescriptions, rehabilitation or activity instructions where relevant, and a clear account of any unresolved finding.
Long-term Crohn’s care continues even if a fistula heals or transplant produces remission. Your doctor may still need to monitor bowel inflammation and adjust maintenance treatment. If a fistula reopens, the first step is reassessment for active inflammation or a new abscess, not an automatic repeat cell injection. After HSCT, relapse or late complications require coordination between your home specialists and the transplant team.
Agree in advance who will obtain new scans, share images securely and decide whether further surgery, medical therapy or another intervention is appropriate. Remote advice can help interpret results, but a complication requiring drainage, admission or urgent testing needs local services. A revision may mean another overseas trip, so establish whether the original provider would reassess you and what that would involve.
Crohn’s terms worth checking in your paperwork
Refractory: The disease has not responded adequately to appropriate treatments. Ask which treatments the specialist means.
Internal opening: The point where a perianal fistula connects to the bowel or anal canal.
Autologous: Cells collected from your own body. It does not mean the procedure is risk-free.
Radiological healing: Improvement seen on a scan. It may be assessed separately from how you feel or whether an opening still drains.
Keep copies of the referral, original scans and reports, final treatment plan, consent, operative or transplant record, product details, discharge summary and follow-up instructions together. That paper trail lets your home team distinguish an expected recovery issue from a problem that needs action.
Discuss your Crohn’s treatment documents before choosing care abroad
If you have a specialist referral and recent reports, a PlacidWay patient coordinator can help you request clearer proposals for the specific Crohn’s problem you need assessed.
Speak with a patient coordinator
References
- National Institute of Diabetes and Digestive and Kidney Diseases — Crohn’s Disease
- NHS — Crohn’s Disease
- U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products, Including Stem Cells and Exosomes
- European Crohn’s and Colitis Organisation — Inflammatory Bowel Disease Resources
- European Society for Blood and Marrow Transplantation — Transplantation Resources
This page is for general information and is not medical advice. Consult a qualified doctor about your diagnosis, treatment options and fitness for travel.
Who stands behind this article
Health content should never be anonymous. Here are the people who wrote and checked it, with credentials you can verify independently.
Usama
As the Editor of Global Stem Cell Therapy, I provide trusted, research-based information on stem cell treatments worldwide. With over a decade of experience in medical tourism, I guide patients toward safe, effective, and affordable therapies.
This author specializes in global healthcare trends and medical education. By focusing on evidence-based practices and a patient-first approach, they provide accessible resources to help readers understand their international treatment options with clarity.
Stem Cell Therapy, Longevity & Regenerative Medicine Specialist
Dr. Alejandro Fernando is a Mexico City-based physician and medical content reviewer focused on stem cell therapy, regenerative medicine, cellular therapy and longevity medicine. His reviewer profile lists medical and postgraduate training related to regenerative medicine, cellular therapy and stem cell biology.
How this article was checked
